Literature DB >> 12901699

Subpial demyelination in the cerebral cortex of multiple sclerosis patients.

Lars Bø1, Christian A Vedeler, Harald I Nyland, Bruce D Trapp, Sverre J Mørk.   

Abstract

The extent and pattern of demyelination in the cerebral cortex was determined in 78 tissue blocks from the brains of 20 multiple sclerosis (MS) patients and 28 tissue blocks from 7 patients without neurological disease. Tissue blocks from 4 predetermined areas (cingulate gyrus, frontal, parietal, and temporal lobe) were studied, irrespective of macroscopically evident MS plaques. All tissue blocks contained cerebral cortex and periventricular and/or subcortical white matter. One hundred and nine demyelinating lesions were detected in the cerebral cortex, of which 92 (84.4%) were purely intracortical and 17 (15.6%) were lesions extending through both white and gray matter areas. In 5 of the 20 MS brains, subpial demyelination was extensive in the 4 widely spaced cortical areas studied, thus considered to represent a general cortical subpial demyelination. The percentage of demyelinated area was significantly higher in the cerebral cortex (mean 26.5%, median 14.1%) than in white matter (mean 6.5%, median 0%) (p = 0.001). Both gray and white matter demyelination was more prominent in the cingulate gyrus than in the other areas examined (p < 0.05). These results indicate that the cerebral cortex is likely to be a predilection site for MS lesions and identify general cortical subpial demyelination as a distinct pattern occurring in a significant subpopulation of MS patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12901699     DOI: 10.1093/jnen/62.7.723

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  198 in total

1.  Natalizumab prevents the accumulation of cortical lesions in relapsing remitting multiple sclerosis: a preliminary report.

Authors:  F Rinaldi; M Calabrese; D Seppi; M Puthenparampil; P Perini; P Gallo
Journal:  Neurol Sci       Date:  2011-01       Impact factor: 3.307

2.  In vivo evidence of disseminated subpial T2* signal changes in multiple sclerosis at 7 T: a surface-based analysis.

Authors:  J Cohen-Adad; T Benner; D Greve; R P Kinkel; A Radding; B Fischl; B R Rosen; C Mainero
Journal:  Neuroimage       Date:  2011-04-13       Impact factor: 6.556

Review 3.  Multiple sclerosis.

Authors:  Alyssa Nylander; David A Hafler
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

Review 4.  Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis.

Authors:  Ranjan Dutta; Bruce D Trapp
Journal:  Prog Neurobiol       Date:  2010-10-12       Impact factor: 11.685

5.  Label-free near-infrared reflectance microscopy as a complimentary tool for two-photon fluorescence brain imaging.

Authors:  Anna Letizia Allegra Mascaro; Irene Costantini; Emilia Margoni; Giulio Iannello; Alessandro Bria; Leonardo Sacconi; Francesco S Pavone
Journal:  Biomed Opt Express       Date:  2015-10-21       Impact factor: 3.732

Review 6.  Grey matter damage in multiple sclerosis: a pathology perspective.

Authors:  Roel Klaver; Helga E De Vries; Geert J Schenk; Jeroen J G Geurts
Journal:  Prion       Date:  2013-01-01       Impact factor: 3.931

Review 7.  [Dementia as a primary symptom in late onset multiple sclerosis. Case series and review of the literature].

Authors:  T Leyhe; C Laske; G Buchkremer; H Wormstall; H Wiendl
Journal:  Nervenarzt       Date:  2005-06       Impact factor: 1.214

Review 8.  Grey matter lesions in MS: from histology to clinical implications.

Authors:  Massimiliano Calabrese; Alice Favaretto; Valeria Martini; Paolo Gallo
Journal:  Prion       Date:  2012-10-23       Impact factor: 3.931

Review 9.  Imaging as an Outcome Measure in Multiple Sclerosis.

Authors:  Daniel Ontaneda; Robert J Fox
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

10.  3D MPRAGE improves classification of cortical lesions in multiple sclerosis.

Authors:  F Nelson; A Poonawalla; P Hou; J S Wolinsky; P A Narayana
Journal:  Mult Scler       Date:  2008-11       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.